Literature DB >> 1118487

Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.

H F Seigler, W W Shingleton, K L Pickrell.   

Abstract

An attempt was made to produce tumor immunity in 193 patients who had melanoma, 160 of whom had metastases and 33 of whom did not. Four stages of treatment are outlined. The patients whose disease was confined to the skin, subcutaneous tissues, and lymph nodes seemed to benefit most. The treatment was of no benefit to patients whose disease had progressed to the visceral, skeletal, or central nervous systems.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1118487

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  3 in total

Review 1.  Developments in Intralesional Therapy for Metastatic Melanoma.

Authors:  Sarah Sloot; Omar M Rashid; Arnod A Sarnaik; Jonathan S Zager
Journal:  Cancer Control       Date:  2016-01       Impact factor: 3.302

Review 2.  Intralesional treatment of metastatic melanoma: a review of therapeutic options.

Authors:  Benjamin Weide; Dario Neri; Giuliano Elia
Journal:  Cancer Immunol Immunother       Date:  2017-01-11       Impact factor: 6.968

3.  Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities.

Authors:  Florencia Paula Madorsky-Rowdo; María Laura Lacreu; José Mordoh
Journal:  Front Immunol       Date:  2012-05-04       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.